Business Context and Reporting Period
This Form 8-K Current Report from Achieve Life Sciences, Inc. (ACHV) covers events occurring on June 7, 2023, specifically the Company's Annual Meeting of Stockholders. The filing details the ratification of corporate governance matters, including the election of directors, approval of auditor appointments, and amendments to the Certificate of Incorporation.
Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes
The primary material change reported is the approval of an amendment to the Company's Second Amended and Restated Certificate of Incorporation. This amendment permits the exculpation of officers in accordance with recent amendments to the Delaware General Corporation Law. The Third Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State on June 8, 2023.
Outlook, Governance, and Voting Results
The Annual Meeting resulted in the following key outcomes:
- Director Elections: All eight nominees (John Bencich, Stuart Duty, Vaughn Himes, Cindy Jacobs, Thomas B. King, Bridget Martell, Thomas Sellig, and Richard Stewart) were elected to the Board of Directors.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Executive Compensation: The non-binding advisory vote to approve executive compensation passed. Stockholders also voted to hold future advisory votes on executive compensation every three years.
- Equity Plan: The 2023 Non-Employee Director Equity Incentive Plan was approved.
Key Facts for Investor Verification
- Verify the filing of the Third Amended and Restated Certificate of Incorporation (Exhibit 3.1) to confirm the legal effect of the officer exculpation amendment.
- Confirm the tenure of the newly elected directors, who serve until the next annual meeting or until their successors are qualified.
- Note the shift in executive compensation advisory voting frequency to a three-year cycle, as approved by stockholders.
- Review subsequent filings (e.g., 10-K or 10-Q) for actual financial performance data, as this 8-K contains no financial metrics.